Assessing the potential for enhanced antibody-dependent cellmediated cytotoxicity (ADCC) by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors Meeting Abstract

  

Authors:	Segal, N. H.; Sharma, M.; Le, D. T.; Ott, P. A.; Ferris, R. L.; Zelenetz, A. D.; Neelapu, S. S.; Levy, R.; Lossos, I. S.; Jacobson, C.; Ramchandren, R.; Godwin, J.; Colevas, A. D.; Meier, R.; Krishnan, S.; Gu, X.; Neely, J.; Suryawanshi, S.; Timmerman, J.
Abstract Title:	Assessing the potential for enhanced antibody-dependent cellmediated cytotoxicity (ADCC) by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors
Meeting Title:	31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016)
Journal Title:	Journal for ImmunoTherapy of Cancer
Volume:	4
Issue:	Suppl. 1
Meeting Dates:	2016 Nov 9-13
Meeting Location:	National Harbor, MD
ISSN:	2051-1426
Publisher:	Biomed Central Ltd
Date Published:	2016-11-16
Start Page:	73
Language:	English
DOI:	10.1186/s40425-016-0173-6
PROVIDER:	manual
Notes:	Meeting Abstract: P259

https://synapse.mskcc.org/synapse/works/has_related_data_chk/143641